Schrodinger, Inc. Common Stock (SDGR) — Analysis Summary
Schrodinger, Inc. Common Stock (SDGR) has a market cap of $1.55B with year-over-year revenue growth of +23.3%. Net margin stands at -40.4%. The stock trades at a P/E ratio of -28.6.
Key Takeaways
- Revenue changed +23.3% year-over-year
- Net margin of -40.4%
- P/E ratio of -28.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SDGR posted revenue growth of +23.3% and trades at a P/E of -28.6.
Schrodinger, Inc. Common Stock (SDGR)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -59.2% — severe operating losses
Net margin at -21.0% — significant losses
Free cash flow turned negative after being positive in the prior period.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
850
Headquarters
NEW YORK, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.